Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in ...

By Vijay Kumar Malesu New research shows that early switching to camizestrant based on ctDNA detection of ESR1 mutations can ...

Zymeworks' collaborator BeOne Medicines secured the approval under the terms of their Asia-Pacific licence and partnership ...

Increased consumption of olive oil may reduce the risk for specific subtypes of breast cancer, according to results of a ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group.

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...